RLAY (Relay Therapeutics Inc) רווח למניה בארבעת הרבעונים האחרונים

Relay Therapeutics (RLAY) relies on partnerships with tech giants to accelerate the discovery of cancer treatments. On GURU.Markets, the relative EPS YoY TTM growth rate reflects profit dynamics, with the value holding around 13.50, which is critical for a non-cyclical sector resilient to crises. Meanwhile, the company is implementing AI protein modeling to create a high-tech pipeline of innovative small molecules.

Profit dynamics are critical for Relay Therapeutics (RLAY), as its Inertia platform creates long-term patent monopolies in oncotherapy. The relative YoY EPS growth over the last 12 months filters out quarterly noise, measuring the real change in net income per share via a rolling annual interval. Analyzing this metric reveals the hidden pace of intellectual property capitalization, confirming the asset's fundamental resilience.